Anti-infective Drugs Market Size, Share & Industry Analysis, By Drug Type (Antibiotics, Antivirals, Antifungals, Others), By Indication (HIV, Pneumonia, Respiratory Infections, Tuberculosis), By Route Of Administration (Oral, Topical, Parenteral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others) and Regional Forecast, 2024-2032

Anti-infective drugs or agents are capable of acting against an infection, by inhibiting the spread of an infectious agent or by killing the infectious agent. The infection causing agents include fungi, virus, bacteria, and macro parasites. Factors such as increase in the number of patients suffering from infectious diseases, extensive research and development efforts pertaining to the development of new drugs, rise in the new drug approvals, and growing awareness among the individuals related to the infectious diseases are expected to accentuate the market growth during the forecast period. For example, in August 2019, Nabriva Therapeutics received USFDA approval for Xenleta (lefamulin), new antibiotic to treat adults with community-acquired bacterial pneumonia.

The anti-infective drugs market is expected to register a significant growth during the forecast period due to factors such rising number of cases of infectious diseases, escalating health-consciousness, growing number of product approvals for the treatment of infectious diseases. However, high cost of the drugs and poor reimbursement policies are the major factors anticipated to hamper the growth of anti-infective drugs market.

Market Segmentation:

Globally, the anti-infective drugs market can be segmented on the basis of the drug type, indication, route of administration, distribution channel and region. Based on the drug type, the market can be segmented into antibiotics, antivirals, antifungals, and others. Based on indication, the market can be segmented into HIV, pneumonia, respiratory infections, tuberculosis, and others. Based on the route of administration, the market can be segmented into oral, topical, and parenteral. Based on distribution channel, the market can be segmented into hospital pharmacies, retail pharmacies, and others. Geographically, the anti-infective drugs market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East and Africa.

Key Players Covered:

Some of the major companies that are present in the anti-infective drugs market are Pfizer Inc., Merck & Co., Inc. Bristol-Myers Squibb Company, Abbott, Novartis AG, Johnson & Johnson Services Inc., Gilead Sciences, Inc., and Astellas Pharma Inc. GlaxoSmithKline plc., Sanofi, and other prominent players.

Key Insights:

• Prevalence of Infectious Diseases by Key Countries/Region


• Key Industry Trends


• Pipeline Analysis


• New Product Launches


• Key Industry Developments Mergers, Acquisitions, And Collaborations

Regional Analysis:

Geographically, the anti-infective drugs market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America is projected to account for maximum share of the anti-infective drugs market. The dominance is attributable to the increasing incidence of infectious diseases, well developed healthcare sector, and high purchasing power for expensive drugs. For instance, according to Center for Disease Control and Prevention, more than 250,000 people in U.S. are diagnosed with pneumonia every year. Europe is expected to hold second largest market share in global market. Increasing geriatric population and highly aware population is likely to spur the market growth in this region. On the other hand, Asia Pacific is expected to register the highest CAGR owing to the rising economic stability, growing awareness among the population and rising prevalence of infectious diseases. The market in Latin America and the Middle East & Africa are in nascent stage. However, growing geriatric population coupled with increasing susceptibility to infectious diseases in these regions are likely to help witness a considerable growth in the market in the upcoming years.

Segmentation

Anti-infective Drugs Market Industry Developments

• In October 2019, Cipla acquired a novel and patented anti-infective drug Elores, from Venus Remedies Ltd.


• In October 2018, Novartis AG entered into a licensing and equity agreement with Boston Pharmaceuticals for the development of three novel anti-infective drug candidates for the treatment of antibiotic resistant gram-negative infections.


• In April 2018, Hansoh Pharma launched an antifungal drug Hengsen (micafungin sodium for injection)